Fagron N.V.
Supplies compounding ingredients and solutions for personalized medicine to healthcare professionals.
FAGR | BR
Overview
Corporate Details
- ISIN(s):
- BE0003874915
- LEI:
- 549300TRKRUFK2RRG779
- Country:
- Belgium
- Address:
- Venecoweg 20A, 9810 Nazareth
- Website:
- https://fagron.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Fagron N.V. is a global pharmaceutical company that specializes in pharmaceutical compounding to advance personalized medicine. The company focuses on optimizing and innovating customized pharmaceutical care for hospitals, pharmacies, clinics, and prescribers. Fagron develops and supplies a wide range of products, including pharmaceutical raw materials, active pharmaceutical ingredients (APIs), excipients, and innovative compounding vehicles such as Pentravan® (a transdermal base) and SyrSpend® (oral suspending vehicles). By providing these solutions, Fagron empowers healthcare professionals to prepare sterile and non-sterile medications tailored to the unique needs of individual patients, thereby widening the therapeutic scope of prescribers worldwide.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-10-09 07:00 |
Earnings Release
Fagron Q3 2025 press release.pdf
|
English | 281.1 KB | ||
| 2025-10-09 07:00 |
Earnings Release
Fagron Q3 2025 press release NL.pdf
|
Dutch | 339.9 KB | ||
| 2025-10-06 07:00 |
M&A Activity
Fagron receives Brazilian antitrust clearance for Purifarma and Injeplast acqui…
|
English | 590.7 KB | ||
| 2025-10-06 07:00 |
M&A Activity
Fagron verkrijgt goedkeuring door de mededingingsautoriteit in Brazilië voor de…
|
Dutch | 488.0 KB | ||
| 2025-09-29 19:00 |
Share Issue/Capital Change
Press release increase share capital 29 September 2025.pdf
|
English | 148.8 KB | ||
| 2025-09-29 19:00 |
Share Issue/Capital Change
Persbericht verhoging kapitaal 29 september 2025.pdf
|
Dutch | 124.3 KB | ||
| 2025-09-25 07:00 |
M&A Activity
Fagron announces the acquisition of UCP in North America and FDA inspection upd…
|
English | 166.2 KB | ||
| 2025-09-25 07:00 |
M&A Activity
Fagron kondigt de overname van UCP in Noord-Amerika aan en een update over de F…
|
Dutch | 172.5 KB | ||
| 2025-07-31 08:22 |
Earnings Release
Fagron delivers strong performance with 11% topline growth and 12% increase in …
|
English | 209.5 KB | ||
| 2025-07-31 08:22 |
Earnings Release
Fagron delivers strong performance with 11% topline growth and 12% increase in …
|
English | 987.2 KB | ||
| 2025-07-31 08:21 |
Earnings Release
Fagron levert sterke resultaten met een omzetgroei van 11% en 12% stijging van …
|
Dutch | 205.8 KB | ||
| 2025-07-31 08:21 |
Earnings Release
Fagron levert sterke resultaten met een omzetgroei van 11% en 12% stijging van …
|
Dutch | 993.4 KB | ||
| 2025-07-31 07:00 |
Interim Report
Fagron - IFS 30-07-2025 EN.pdf
|
English | 1.6 MB | ||
| 2025-07-31 07:00 |
Interim Report
Fagron - IFS 30-07-2025 NL.pdf
|
Dutch | 1.6 MB | ||
| 2025-07-31 07:00 |
Earnings Release
Fagron - H1 2025 PR EN.pdf
|
English | 987.2 KB |
Automate Your Workflow. Get a real-time feed of all Fagron N.V. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Fagron N.V.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Fagron N.V. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-05-23 | Pulido Andrew | Executive member | Sell | 85,000 | 1,803,351.50 EUR |
| 2025-05-22 | Pulido Andrew | Executive member | Buy | 85,000 | 1,617,550.00 EUR |
| 2025-05-02 | De Jong Cornelia Neeltje | Board | Sell | 12,689 | 263,834.55 EUR |
| 2025-04-30 | De Jong Cornelia Neeltje | Board | Sell | 229 | 4,660.15 EUR |
| 2025-04-29 | De Jong Cornelia Neeltje | Board | Sell | 10,000 | 201,500.00 EUR |
| 2025-03-28 | J. Verlinden | Other | Buy | 24,551 | 453,702.48 EUR |
| 2025-03-28 | J. Verlinden | Other | Sell | 17,930 | 344,047.56 EUR |
| 2025-03-27 | Padilla Rafael | Board | Buy | 78,469 | 1,450,107.12 EUR |
| 2025-03-27 | De Jong Cornelia Neeltje | Board | Buy | 45,418 | 839,324.64 EUR |
| 2025-02-21 | Bakker Vera | Executive member | Buy | 773 | 15,000.00 EUR |
